Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients

NCT05361057 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

20

Enrollment

OTHER

Sponsor class

Stopped The research center has conducted a more comprehensive study.

Conditions

Acute Myeloid Leukemia
Measurable Disease

Interventions

DRUG: Venetoclax, Azacitidine
DRUG: Venetoclax, daunorubicin, cytarabine

Sponsor

Institute of Hematology & Blood Diseases Hospital, China